ReviewThe Journal of infectious diseases2017
White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.
Review in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Multiplexing antibiotic screening assay in droplet microfluidics.Scientific reports · 2026Article
- Hydrodistillation, comparative analysis and optimization of essential oils from Thymus schimperi R, Thymus serrulatus R, and Ocimum lamiifolium Hochst ex Benth.Scientific reports · 2026Article
- Article
- Structure-Activity Relationship of Pyrrolidine Pentamine Derivatives as Inhibitors of the Aminoglycoside 6'-Antibiotics (Basel, Switzerland) · 2024Article
- Platelet-rich plasma attenuates the UPEC-induced cystitis via inhibiting MMP-2,9 activities and downregulation of NGF and VEGF in Canis Lupus Familiaris model.Scientific reports · 2024Article
- Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study.Journal of pharmaceutical policy and practice · 2023Article
- Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.Antimicrobial agents and chemotherapy · 2022Review
- Current Knowledge on the Bioavailability of Thymol as a Feed Additive in Humans and Animals with a Focus on Rabbit Metabolic Processes.Animals : an open access journal from MDPI · 2022Review
- Algal Metabolites Can Be an Immune Booster against COVID-19 Pandemic.Antioxidants (Basel, Switzerland) · 2022Review
- Burden of Antimicrobial Resistance: Compared to What?Epidemiologic reviews · 2022Article
- The immune responses to differentFrontiers in immunology · 2022Review
- Potential Anti-Antioxidants (Basel, Switzerland) · 2021Review
- Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses.Antibiotics (Basel, Switzerland) · 2021Review
- Evaluation of antimicrobial activity of bacterial symbionts isolated from wild field cockroachSaudi journal of biological sciences · 2021Article
- Inhibition of Aminoglycoside 6'-Biomedicines · 2021Article
- Type 3 secretion system 1 of Salmonella typhimurium and its inhibitors: a novel strategy to combat salmonellosis.Environmental science and pollution research international · 2021Review
- Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation.Antibiotics (Basel, Switzerland) · 2021Review
- Sulfaguanidine Hybrid with Some New Pyridine-2-One Derivatives: Design, Synthesis, and Antimicrobial Activity against Multidrug-Resistant Bacteria as Dual DNA Gyrase and DHFR Inhibitors.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.